PMID- 22706847
OWN - NLM
STAT- MEDLINE
DCOM- 20130620
LR  - 20220321
IS  - 1573-7233 (Electronic)
IS  - 0167-7659 (Linking)
VI  - 31
IP  - 3-4
DP  - 2012 Dec
TI  - Galectin-1 as a potent target for cancer therapy: role in the tumor 
      microenvironment.
PG  - 763-78
LID - 10.1007/s10555-012-9388-2 [doi]
AB  - The microenvironment of a tumor is a highly complex milieu, primarily 
      characterized by immunosuppression, abnormal angiogenesis, and hypoxic regions. 
      These features promote tumor progression and metastasis, resulting in poor 
      prognosis and greater resistance to existing cancer therapies. Galectin-1 is a 
      beta-galactoside binding protein that is abundantly secreted by almost all types of 
      malignant tumor cells. The expression of galectin-1 is regulated by 
      hypoxia-inducible factor-1 (HIF-1) and it plays vital pro-tumorigenic roles 
      within the tumor microenvironment. In particular, galectin-1 suppresses T 
      cell-mediated cytotoxic immune responses and promotes tumor angiogenesis. 
      However, since galectin-1 displays many different activities by binding to a 
      number of diverse N- or O-glycan modified target proteins, it has been difficult 
      to fully understand how galectin-1 supports tumor growth and metastasis. This 
      review explores the importance of galectin-1 and glycan expression patterns in 
      the tumor microenvironment and the potential effects of inhibiting galectin-1 as 
      a therapeutic target for cancer treatment.
FAU - Ito, Koichi
AU  - Ito K
AD  - School of Medical Science, Griffith Health Institute, Griffith University, 
      Parklands Drive, Southport, Queensland 4222, Australia. koichi50@gmail.com
FAU - Stannard, Kimberley
AU  - Stannard K
FAU - Gabutero, Elwyn
AU  - Gabutero E
FAU - Clark, Amanda M
AU  - Clark AM
FAU - Neo, Shi-Yong
AU  - Neo SY
FAU - Onturk, Selda
AU  - Onturk S
FAU - Blanchard, Helen
AU  - Blanchard H
FAU - Ralph, Stephen J
AU  - Ralph SJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Cancer Metastasis Rev
JT  - Cancer metastasis reviews
JID - 8605731
RN  - 0 (Galectin 1)
RN  - 0 (Thiogalactosides)
RN  - 80441-61-8 (thiodigalactoside)
SB  - IM
MH  - Animals
MH  - Cell Hypoxia
MH  - Galectin 1/*antagonists & inhibitors/chemistry/*physiology
MH  - Humans
MH  - Immune Tolerance
MH  - Neoplasm Metastasis
MH  - Neoplasms/*drug therapy/immunology
MH  - Neovascularization, Pathologic/etiology
MH  - T-Lymphocytes/immunology
MH  - Thiogalactosides/pharmacology
MH  - *Tumor Microenvironment
EDAT- 2012/06/19 06:00
MHDA- 2013/06/21 06:00
CRDT- 2012/06/19 06:00
PHST- 2012/06/19 06:00 [entrez]
PHST- 2012/06/19 06:00 [pubmed]
PHST- 2013/06/21 06:00 [medline]
AID - 10.1007/s10555-012-9388-2 [doi]
PST - ppublish
SO  - Cancer Metastasis Rev. 2012 Dec;31(3-4):763-78. doi: 10.1007/s10555-012-9388-2.